From the just released AT1 quarterly. They had revenue of $2.2M...

From the just released AT1 quarterly. They had revenue of $2.2M for the qtr.

The Company continues to make sales of its professional-use tests into several channels
although the overall level of demand for rapid antigen tests has reduced as the Omicron peak
has subsided. Demand for professional testing remains in the resources sector and among
corporates, with demand in the aged care sector having significantly reduced due to a change
to mandatory requirements in that industry. Testing levels across smaller organisations have
also seen a contraction in recent months. The Company does not anticipate a return to peak
demand unless or until a new variant of concern emerges and has managed its stock position
accordingly.
The Company continues to work actively to obtain TGA approval for a COVID-19 rapid antigen
self-test and is working with the listed manufacturer of its antigen test to deliver additional
clinical information to the TGA, including data related to the detection of the Omicron variant